P27 V109G polymorphism is associated with lymph node metastases but not with increased risk of breast cancer

Journal of Experimental and Clinical Cancer Research

Volumn 26, Issue 1, 2007, Pages 133-140

  Naidu, Rakesh ^a   Har, Y C ^a,b   Taib, N A M ^a,b  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

Breast cancer; P27; Polymorphism

Indexed keywords

PROTEIN P27;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER INVASION; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALAYSIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLYCINE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPH NODES; LYMPHATIC METASTASIS; MALAYSIA; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PHENOTYPE; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROGNOSIS; RECEPTORS, ESTROGEN; RISK ASSESSMENT; RISK FACTORS; VALINE;

EID: 34247501138     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Sherr C.J.: Cancer cell cycles. Science 274:1672-1677, 1996.
2. KIP1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66, 1994.
3. Xiong Y., Hannon G.J., Zhang H., Casso D., Kobayashi R., Beach D.: p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704, 1993.
4. Toyoshima H., Hunter T.: p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 78:67-74, 1994.
5. Slingerland J., Hengst L., Pan C., Alexander D., Stampfer M., Reed S.: A novel inhibitor of cyclin-Cdk activity detected in TGF-β-arrested epithelial cells. Mol. Cell. Biol. 14:3683-3694, 1994.
6. Pagano M., Tam S.W., Theodoras A.M., et al.: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682-685, 1995.
7. Slingerland J., Pagano M.: Regulation of the cdk inhibitor p27 and its deregulation in cancer. J. Cell Physiol. 183:10-17, 2000.
8. KIP1 protein: Prognostic implications in primary breast cancer. Nat. Med. 3:227-230, 1997.
9. KIP1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 3:222-225, 1997.
10. Spataro V.J., Litman H., Viale G., et al.: Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V. Cancer 97:1591-1600, 2003.
11. Tan P., Cady B., Wanner M., et al.: The cell cycle inhibitor p27 is an independent prognostic marker in small (TIa,b) invasive breast carcinomas. Cancer Res. 57:1259-1263, 1997.
12. KIP1 and degree of malignancy in human breast and colorectal cancers.Proc. Natl. Acad. Sci. USA 94:6380-6385, 1997.
13. KIP1 and apoptosis in human breast cancer. Br. J. Cancer 79:1572-1578, 1999.
14. KIP1 protein levels independently predict outcome after breast cancer. J. Clin. Oncol. 18:4045-4052, 2000.
15. KIP1 expression and interaction with other cell cycle-associated proteins in mammary carcinoma. J Pathol 1999;187:200-206.
16. KIP1 expression in breast carcinomas: An immunohistochemical study on 512 patients with long-term follow-up. Int. J. Cancer 89:236-241, 2000.
17. KIP1 in human malignancies. Cancer Res. 55:2266-2269, 1995.
18. Kibel A.S., Suarez B.K., Belani J., et al: CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res. 63:2033-2036, 2003.
19. KIP1 genes with susceptibilities of esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma. Ai Zheng. 25:194-199, 2006.
20. Li G., Sturgis E.M., Wang L.E., et al.: Association between the V109G polymorphism of the p27 gene and the risk and progression of oral squamous cell carcinoma. Clin. Cancer Res. 10:3996-4002, 2004.
21. Chang B.L., Zheng S.L., Isaacs S.D., et al.: A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer. Cancer Res. 64:1997-1999, 2004.
22. Tigli H., Buyru N., Dalay N.: Molecular analysis of the p27/kip1 gene in breast cancer. Mol. Diagn. 9:17-21, 2005.
23. Schondorf T., Eisele L., Gohring U.J.: The V109G polymorphism of the p27 gene CDKN1B indicates a worse outcome in node-negative breast cancer patients. Tumor Biol. 25:306-312, 2004.
24. Lim G.C.C., Halimah Y.: Second Report of the National Cancer Registry. Cancer Incidence in Malaysia 2003. National Cancer Registry. Kuala Lumpur 2004.
25. Elston C.W., Ellis I.O.: Pathological prognostic factors in breast cancer I. Histopathology 19:403-410, 1991.
26. Bloom H.I.G., Richardson W.W.: Histological grading and prognosis. Br. J. Cancer 11:359-377, 1957.
27. Pertschuk P., Kim D.S., Nayer K., et al.: Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Cancer 66:1663-1670, 1990.
28. KIP1 in primary breast carcinomas. Hum. Genet. 97: 91-94, 1996.
29. Kibel A.S., Christopher M., Faith D.A., Bova G.S., Goodfellow P.J., Issac W.B., et al.: Methylation and mutational analysis of p27 (kip1) in prostate carcinoma. Prostate 48:248-253, 2001.
30. KIP1 accumulation during the cell cycle. Science 271:1861-1864, 1996.
31. Loda M., Cukor B., Tam S.W., et al.: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med. 3:231-234, 1997.